市場調査レポート

二重特異性抗体:治験追跡調査

Bispecific Antibodies: Clinical Trial Tracker

発行 ROOTS ANALYSIS 商品コード 296324
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
二重特異性抗体:治験追跡調査 Bispecific Antibodies: Clinical Trial Tracker
出版日: 2014年02月13日 ページ情報: 英文
概要

二重特異性抗体(bsAbs)は異なるエピトープを標的にする2つのモノクロナール抗体(または組織)を結合して生成される人工的な抗体です。結果として生じる抗体は、2つまたは3つの異なるエピドープを同時に結びつける親和性を持っています。

当レポートでは、二重特異性抗体(bsAbs)の治験状況について調査し、臨床開発における企業、開発段階、二重特異性システム、および適応症別の内訳、治験における段階、状況、適応症、スポンサータイプ、地域、分子および主要国別の内訳などを分析しており、臨床・前臨床開発における分子のパイプライン詳細、SWOT分析などをまとめ、概略下記の構成で取り上げております。

イントロダクション・パイプライン詳細

  • セクション1:市場概要
  • セクション2:ダッシュボード:パイプライン分析
  • セクション3:臨床開発における分子:試験詳細
  • セクション4:前臨床における分子:試験詳細
  • セクション5:試験対象患者基準/除外基準

市場予測

  • セクション6:市場予測:前提条件
  • セクション7:市場予測:詳細
  • セクション8:比較予測シナリオ

産業分析

  • セクション9:産業のSWOT分析

図表リスト

企業リスト

目次
Product Code: CT10002

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently.

Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only one bsAb, Removab, approved for malignant ascites is available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.

Table of Contents

Introduction and Pipeline Details

  • Section 1: Market Overview
  • Section 2: Dashboard: Pipeline Analysis
  • Section 3: Molecules in Clinical Development: Trial Details
  • Section 4: Molecules in Preclinical Development: Trial Details
  • Section 5: Inclusion / Exclusion Criteria

Market Forecast, 2013 - 2023

  • Section 6: Market Forecast: Assumptions
  • Section 7: Market Forecast: Details
  • Section 8: Comparative Forecast Scenarios

Industry Analysis

  • Section 9: Industry SWOT Analysis

List of Figures

Pipeline Details

  • Figure 1: Bispecific Antibodies in Clinical Development: Distribution by Companies
  • Figure 2: Bispecific Antibodies in Clinical Development: Distribution by Highest Phase of Development
  • Figure 3: Bispecific Antibodies in Clinical Development: Distribution by Type of Bispecific System
  • Figure 4: Bispecific Antibodies in Clinical Development: Distribution by Indication
  • Figure 5: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
  • Figure 6: Bispecific Antibodies Clinical Trials: Distribution by Trial Status
  • Figure 7: Bispecific Antibodies Clinical Trials: Distribution by Trial Phase
  • Figure 8: Bispecific Antibodies Clinical Trials: Distribution by Indication
  • Figure 9: Bispecific Antibodies Clinical Trials: Distribution by Sponsor Type
  • Figure 10: Bispecific Antibodies Clinical Trials: Distribution by Region
  • Figure 11: Bispecific Antibodies Clinical Trials: Distribution by Molecules and Countries (Matrix View)
  • Figure 12: Bispecific Antibodies Clinical Trials: Distribution by G7 Countries
  • Figure 13: Bispecific Antibodies Clinical Trials: Distribution by EU5 Countries
  • Figure 14: Bispecific Antibodies in Preclinical Development: Distribution by Indication

Market Forecast

  • Figure 15: Bispecific Antibody Therapeutics Market Forecast, Base Scenario (USD MM)
  • Figure 16: Bispecific Antibody Therapeutics Market Forecast, Scenario Comparison (USD MM)

List of Tables

Pipeline Details

  • Table 1: Molecules in Clinical Development: Pipeline Details
  • Table 2: Molecules in Preclinical Development: Pipeline Details

Market Forecast

  • Table 3: Expected Launch Year of Bispecific Antibodies in Clinical Development

Industry Analysis

  • Table 4: SWOT Analysis

Listed Companies

The following companies and organisations have been mentioned in the report:

  • 1.AbbVie
  • 2.Ablynx
  • 3.Adimab
  • 4.Affimed Therapeutics
  • 5.AGO Study Group
  • 6.Allergan
  • 7.Alligator Bioscience
  • 8.Allozyne
  • 9.Ambrx
  • 10.Amgen
  • 11.Amphivena Therapeutics Inc.
  • 12.Baliopharm
  • 13.Barbara Ann Karmanos Cancer Institute
  • 14.Bayer
  • 15.Beijing ABT Genetic Engineering Technology Co.
  • 16.Biogen Idec
  • 17.Bioline Rx
  • 18.Biotecnol
  • 19.Boehringer Ingelheim
  • 20.Celgene
  • 21.Centre René Gauducheau
  • 22.Chiome Bioscience
  • 23.Chugai
  • 24.Dutalys
  • 25.Eddingpharm
  • 26.Eli Lilly
  • 27.Emergent Biosolutions
  • 28.Fabion Pharmaceuticals
  • 29.Fresenius Biotech
  • 30.F-star
  • 31.Ganymed Pharmaceuticals
  • 32.Garden State Cancer Center at the Center for Molecular Medicine and Immunology
  • 33.Genentech
  • 34.Genmab
  • 35.Gilead
  • 36.Grupo Espa&ntilede;ol de Investigación en Cáncer de Ovario; Neovii Biotech
  • 37.GSK
  • 38.Gustave Roussy, Cancer Campus, Grand Paris
  • 39.Ho Research Consortium
  • 40.ImClone System
  • 41.Immunomedics
  • 42.Innovent Biologics Inc.
  • 43.Institut National de la Santé Et de la Recherche Médicale, France
  • 44.International Joint Cancer Institute, the Second Military Medical University
  • 45.Janssen Biotech
  • 46.Jsehouli
  • 47.Krankenhaus Nordwest
  • 48.Kyowa Hakko Kirin
  • 49.MacroGenics
  • 50.Masonic Cancer Center, University of Minnesota
  • 51.MediaPharma S.R.L
  • 52.MedImmune
  • 53.Memorial Sloan-Kettering Cancer Center
  • 54.Merck
  • 55.Merrimack Pharmaceuticals
  • 56.Merus B.V.
  • 57.Molecular Partners AG
  • 58.Nantes University Hospital
  • 59.National Cancer Institute
  • 60.National Engineering Research Center for Antibody Medicine
  • 61.NeoPharm
  • 62.Neovii Biotech
  • 63.Novartis
  • 64.NovImmune
  • 65.Numab
  • 66.OncoMed Pharmaceuticals
  • 67.Paktis Antibody Services GmbH
  • 68.Pfizer
  • 69.PharmAbcine
  • 70.PLA General Hospital Cancer Center, Beijing
  • 71.Protheragen
  • 72.Radboud University
  • 73.Regeneron Pharmaceuticals
  • 74.Roche
  • 75.Roger Williams Medical Center
  • 76.Sanofi
  • 77.School of Medicine, Shanghai Jiao Tong University
  • 78.Sea Lane Biotechnologies
  • 79.Servier
  • 80.State Key Laboratory of Antibody Medicine and Targeted Therapy
  • 81.Sutro Biopharm
  • 82.Synergys Biotherapeutics Inc.
  • 83.Synimmune GmbH
  • 84.Technische Universität München
  • 85.Trion Pharma
  • 86.University Hospital Tuebingen
  • 87.University Hospital Tuebingen
  • 88.University Witten/Herdecke
  • 89.Xencor
  • 90.Zymeworks
  • 91.Zyngenia
Back to Top